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Diabetic retinopathy remains asymptomatic until its late stages but remains a leading cause of vision 
impairment and blindness. We studied quality of life and the ability to deal with the discomfort 
deriving from the presence of a chronic disease in patients with Type 1 Diabetes and different stages of 
retinopathy.  
Methods. 
Multicenter collaborative observational study involving 9 centers screening for retinopathy in different 
areas of Italy. The National Eye Institute 25-item Visual Functioning Questionnaire and the Locus of 
Control tool were administered to 449 people with Type 1 diabetes between February 2016 and March 
2018. Socio-demographic and clinical data were collected. 
Results. 
On multivariable analysis, severe retinopathy associated with worse scores for General Vision, Ocular 
Pain, Near Vision Activities, Distance Vision Activities, Driving, Color Vision, Peripheral Vision, and 
lower values of Internal Control, independently of visual acuity. Women had a perception of worse 
General Health, Distance Vision Activities and Driving, and lower Internal Control and Trust in 
Others. Worse scores for Visual Specific Social Functioning, Visual Specific Mental Health, Visual 
Specific Role Difficulties, Visual Specific Dependency and Peripheral Vision were associated with 
higher HbA1c levels. Fatalism increased with rising HbA1c levels. 
Conclusions. 
These results confirm that a gap exists between patients’ knowledge and expectations on retinopathy 
and providers’ expertise and assumptions. To bridge this gap, patient-centered education and engaging 
approaches may be more effective than simple information given during consultations. 
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Diabetic retinopathy (DR) remains asymptomatic until it reaches its late stages but is still a leading 
cause of vision impairment and blindness in people with diabetes (1-3). The prevalence of DR is about 
70 % in patients with type 1 diabetes and 40 % among those with type 2, with no differences by 
gender (3). Its annual incidence ranges from 2.2% to 12.7% and progression rate from 3.4% to 12.3% 
(3). Although optimal control of blood glucose and blood pressure can prevent DR and retard its 
progression, they are not always achieved (4). In addition, even among patients well within treatment 
targets, retinopathy may develop and progress (4). Hence, despite regular control visits, treatment by 
laser photocoagulation or other invasive therapies may become necessary (4-6).  
Well-organized procedures to screen for sight-threatening DR reduce the risk of visual loss, and 
success of prevention strategies depends on planning and instrumentation as well as patient 
involvement (5,6). However, people with diabetes are not always able to understand the link between 
eye problems, poor metabolic control and the importance of regular eye exams (7). In addition, they 
may have difficulties in coping with the complications of DR (7), in terms of worsening visuo-specific 
quality of life, deterioration in social and relational aspects and daily tasks. All this may lead to 
depression, social isolation, and difficulties at home, in school, or at work. As a preliminary step to 
make integrated, people-centered health services work by fostering patient engagement (8), we studied 
quality of life and the ability to deal with the problematic situations that derive from the presence of a 
chronic disease in patients with Type 1 Diabetes and different stages of diabetic retinopathy.  
 
Patients and Methods. 
This was a multicenter collaborative and observational study involving 9 centers dedicated to the 
screening of DR in different geographical areas of Italy. Patients attending their DR screening clinics 
were enrolled consecutively. Approval of the institutional Ethics Committees by Città della Salute e 
della Scienza di Torino, Ordine Mauriziano di Torino, was extended to all participating center. All 
patients signed their informed consent to participate. 
Socio-demographic data were collected from digital medical records and are shown in Table 1. These 
include gender, age, Best Corrected Visual Acuity (BCVA), duration of diabetes, schooling, living 
alone, occupation, smoking habits, physical activity, presence of hypertension, HbA1c, frequency of 
self-monitoring of blood glucose, daily units of insulin, use of continuous insulin infusion and number 
of hypoglicaemic episodes or severe hypoglicaemias requiring administration of i.m. glucagon over the 
previous six months. Frequency of diabetes visits and eye visits over the previous year, reasons for eye 
consultation, severity of DR, cataract and previous laser treatment are also detailed in Table 1.  
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The patients were offered 3 options to answer the question about their reasons for attending the eye 
clinic: Requested by diabetologist; Requested by the patient in the absence of visual symptoms; 
Requested by patient because of visual symptoms. 
Screening for DR was carried out according to Italian guidelines (9). Briefly, the procedure includes 
collection of patients' data, measurement of BCVA, pupil dilation by 1% tropicamide eyedrops, and 
colour photographs of 2 x 45° fields (macula and nasal to disc). The retinal photographs were graded 
by expert ophthalmologists in each centre, according to routine clinical practice, and DR was classified 
as: absent, mild (microaneurysims only or isolated blot haemorrhages) corresponding to ETDRS grade 
20 (10), moderate (ETDRS grade 35), severe non proliferative (ETDRS grades 47-53), and 
proliferative. Previous laser treatment was assessed from the patient’s history. 
Psychometric evaluation 
Two questionnaires, the National Eye Institute 25-item Visual Functioning (NEI VFQ-25) (11-13) and 
the Locus of Control tool (14), were administered to 449 people with type 1 diabetes, aged 18 - 80 
years, attending DR screening clinics between February 2016 and March 2018.  
The providers involved in the study were trained to follow the correct procedures for the 
administration of the questionnaires and collect variables. 
The original NEI VFQ-25 Questionnaire had been translated into Italian and validated (13). It includes 
25 items grouped into 12 subscales: General Health, General Vision, Ocular Pain, Difficulty with 
Near-vision Activities, Difficulty with Distance-vision Activities, Vision Specific Social Functioning, 
Vision Specific Mental Health, Vision Specific Role Difficulties, Visual Specific Dependency, Driving 
Difficulties, Difficulty with Color Vision, Difficulty with Peripheral Vision.  
Each subscale is converted to a score between 0 and 100, higher scores indicating better vision-specific 
quality of life. The questionnaire takes on average approximately 10 minutes to administer in the 
interviewer format (13).  
The Locus of Control questionnaire of Peyrot and Rubin includes a set of 18 statements measuring 
expectancies of Internal, Chance, and “Powerful Others” control over diabetes-related health 
outcomes. The final questionnaire consists of 6 items for each of 3 domains measuring the degree to 
which subjects consider their diabetes to be under their own control, dependent on others, or dependent 
on chance or fate (14). 
After completing the questionnaires, the patients were given the opportunity to answer a final open 
question: “Thank you for answering these questions and giving your opinion. If you wish to add further 
comments please write them on this page.” 
Statistical analysis  
Results are shown as relative frequencies (%) for categorical data and mean ± SD or median and 
interquartile range (IQR) for continuous variables, as appropriate. 
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The chi-square test for categorical variables and analysis of variance (ANOVA) with Bonferroni 
correction, or Kruskal-Wallis test in case of nonparametric distribution, for continuous variables were 
carried out to assess whether significant differences could be detected among 4 DR stages (no; mild-
moderate; severe; previous laser treatment) for socio-demographic and clinical data, and to compare 
the above stages of DR for the items from the NEI VFQ-25 and Locus of Control questionnaires. Chi-
square test for categorical variables and t or Wilcoxon test for continuous variables were used to 
compare the severe DR and laser treatment groups. 
Multivariable analysis models were then used to investigate the independent effects of different stages 
of DR on vision-related quality of life and Locus of Control. Linear regression models were fit using 
scores from the different subscales of  the NEI VFQ-25 and Locus of Control questionnaires as 
dependent variables and the 3 stages of DR severity (no, mild-moderate and severe), gender, duration 
of diabetes, schooling, smoking habits, hypertension and HbA1c as independent variables. 
For all tests, a p-value of less than 5% was considered significant. 
All analyses were performed with Stata 14. 
 
Results 
Four hundred and forty-nine people with type 1 diabetes were recruited and administered the two 
questionnaires. Assessable fundus photographs were available for 443 of them, 156 with no 
retinopathy, 115 with mild-moderate retinopathy, 151 with severe retinopathy and 21 who had 
received laser treatment.  
Socio demographic and Clinical data 
Table 1 shows that patients without DR were younger and had shorter disease duration (p<0.001). 
People with Severe DR had worse BCVA (p<0.001), longer diabetes duration (p<0.001), were more 
likely to be hypertensive, had lower schooling and were more likely to be housewives/retired and self-
employed (p=0.014). As the severity of retinopathy progressed, the number of eye visits per year 
increased (p<0.001), in most cases as a consequence of visual symptoms (p<0.001).  
Compared with the patients with severe DR, those who had received Laser Treatment were younger 
(41.6±12.0 vs 47.9±9.5; 0.0063) and had shorter diabetes duration (28.8±12.4 vs 35.1±10.2; 0.0038), 
but did not differ significantly for any of the other variables considered. 
Psychometric evaluation. 
Compared to the patients with Severe DR, those who had received laser treatment had worse scores for 
General Health (42.5±24.5 vs 58.3±28.2; 0.0183) and Visual Specific Dependency (91.2±20.3 vs 
97.1±10.4; 0.04). However, because of their small number, patients who had received laser treatment 
were not included in Table 2, summarizing the data on vision-related quality of life, and the following 
multivariable analysis (Table 3).  
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Compared with patients with no and mild-moderate DR, those with severe DR had worse scores for 
General Vision, Ocular Pain, Near Vision Activities, Distance Vision Activities, Driving, Color 
Vision, and Peripheral Vision (p<0.001). Visual Specific Mental Health was significantly lower in the 
Severe compared to the Mild-Moderate DR group only (0.046). 
In terms of Locus of Control, the patients with Severe DR had lower scores for Internal Control than 
those without DR. 
On multivariable analysis (Table 3), General Vision (p<0.001), Ocular Pain (p<0.01), Near Vision 
Activities (p<0.05), Distance Vision Activities (p<0.01), Driving (p<0.05), Color Vision (p<0.05), and 
Peripheral Vision (p<0.001) remained significantly worse in the people with Severe DR.  
Adding BCVA as an independent variable to all the models did not change the overall results, except 
for Driving, which improved with better BCVA (β 1.12 p=0.02), whereas Severe DR was no longer 
significant.  
Multivariable analysis also showed that General Health (p<0.01), Distance Vision Activities (p<0.001) 
and Driving (p<0.01) were lower among women. Interestingly, General Health improved with longer 
duration of disease (p<0.01), while Driving worsened in the presence of hypertension (p<0.05). 
Visual Specific Social Functioning (p<0.05), Visual Specific Mental Health (p<0.05), Visual Specific 
Role Difficulties (p<0.05), Visual Specific Dependency (p<0.001), Peripheral Vision (p<0.05) were 
negatively modified by increasing glycated hemoglobin levels. 
The Locus of Control questionnaire showed lower values of Internal Control in the presence of Severe 
DR (p<0.01). Lower levels of Internal Control (p<0.01) and Trust in Others (p<0.05) were observed 
among women. Lower Fatalism (p<0.01) and Trust in Others (p<0.05) were found among people with 
higher education. People with higher levels of Trust in Others were more frequently hypertensive 
patients (p<0.001) and Fatalism increased with increasing glycated hemoglobin (p<0.05). 
 
Discussion. 
The NEI VFQ-25 has demonstrated consistency and validity to assess the impact of retinopathy on the 
life of people with diabetes in previous clinical studies (15,16). DR is a common, potentially blinding, 
microvascular complication and studies exploring psychological adjustment in diabetic individuals 
showed that even those with mild DR express feelings of uncertainty and vulnerability at the prospect 
of losing vision (17). Key risk factors include hyperglycaemia, dyslipidaemia, hypertension and long 
duration of disease as the majority of patients will have some degree of retinopathy after 20 years of 
diabetes (18-20).  
Diabetic Retinopathy is classified into mild, moderate and severe non-proliferative or proliferative 
according to the presence and severity of microaneurysms, intraretinal haemorrhages, hard exudates, 
cotton wool spots, venous caliber abnormalities, intraretinal microvascular abnormalities and 
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appearance of fibro-vascular proliferations (21). Visual acuity and visual functioning are usually not 
affected in its mild and moderate stages. However, as the disease progresses to severe retinopathy, 
visual impairment may occur, resulting in difficulties with day to day tasks, driving and mobility (22).  
Few patients in this study had severe visual impairment despite retinopathy in different stages, severe 
in about one third of cases and already treated by photocoagulation in 21. However, the NEI VFQ-25 
questionnaire was able to detect subtle abnormalities in most dimensions, confirming previous data in 
the literature. We could confirm a link between psychological dimensions and daily activities 
previously reported by other studies that have shown the high emotional and social impact of DR 
(23,24). Indeed, people with severe DR may experience pain and difficulties in carrying out ordinary 
accomplishments such as cooking or daily family endeavors. Severe DR modifies the ability to engage 
in Distance Activities and social life in such cultural behaviors as viewing a film or participating in a 
sporting event. In this study people with type 1 diabetes and severe DR face difficulties in their daily 
existence in terms of autonomous driving of motor vehicles, color discrimination and moving in space 
because of difficulties with peripheral vision (24). Recurrent thinking about visual difficulties in 
addition to the perception of widespread discomfort was associated with high levels of glycated 
hemoglobin (25). 
Severe DR was associated with reduced Internal Control of diabetes. The concept of Locus of Control 
denotes a context of outer‐ or inner‐directed behavior in various situations faced by patients in daily 
life. Individuals who firmly believe in their ability to cope with anything that might happen to them are 
regarded as having an internal locus of control. In contrast, placing responsibilities outside oneself is 
considered an externalized locus of control. As such, the locus of control plays a major role in driving 
emotional reactions and behavior. A high level of education seems to provide more conceptual 
sturdiness to cope with the disease, as perceived autonomy support, autonomy-driven motivation and 
self-perceived competence play a significant role in explaining self-esteem among adults with sub 
optimally regulated Type 1 diabetes (26, 27). 
In this study, women were particularly affected in the dimension of Trust in Others, suggesting 
changes in their life of relationships and lack of network support useful to cope with the discomfort of 
the disease. A lady wrote “Diabetes struck when I was 12. I reacted badly. I felt different and sick. It 
took a lot of time and a lot of psychotherapy to fix the problem. It is not true that you can have a 
normal life. With diabetes you may have a good life but only with commitment, consistency and help”. 
That women experience more profound discomfort in the presence of a complication had already been 
reported (28). In this sense, psychological support is important to help people with type 1 diabetes 
overcome the stigma of chronicity, as disease management may be hampered if a central self-concept 
of illness prevails. Improvement in treatment satisfaction and impact of disease support the efficacy of 
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structured sustained educational processes, while increased self-esteem may be associated with 
strengthened problem-solving strategies (27,28). Both require patient-centered approaches. 
The increased sense of Trust in Others related to hypertension, and a stronger sense of fatalism related 
to high levels of glycated hemoglobin suggest that people do not benefit from a tendency to completely 
delegate their health care to others (29). These observations indicate that tackling glycaemic control is 
important not only to avoid complications but also to prevent patients from resorting to avoidant 
coping strategies. Furthermore, given the interplay between perceived control and passive coping, 
intervention efforts should include both cognitive and behavioral components to be effective (29).  
This study shows that patients with type 1 diabetes had not received optimal eye care on a regular 
basis, as in many cases the visit was a consequence of their own perception of having visual 
symptoms, while in other cases it was the patients themselves who requested to have their eyes 
checked in the absence of symptoms. Guidelines in Italy (9) recommend proactive regular screening at 
least every other year or more frequently in the presence of diagnosed DR, but many people with 
diabetes do not receive regular ophthalmological care aimed at preventing visual impairment and 
blindness (30). Some patients have developed sufficient self-management skills to make them decide 
to be seen by an ophthalmologist. Among the responses collected from people with diabetes in this 
study, a sentence is indicative “I am aware of the risks and complications, but being careful and trying 
to maintain good control and a good relationship with your doctor helps to prevent both”. Overall, 
however, the good levels of BCVA in this study suggest that a mix of patient- and doctor-directed eye 
care had resulted in the prevention of severe visual loss. Overall, the study supports the notion that 
both type 1 diabetes per se and DR modify the perception of quality of life. One of our patients wrote 
“Managing diabetes is complex and 90% depends on active participation of the person with diabetes, 
how much he/she knows about and accepts the disease. If you know it, you can live better with 
diabetes. To deny it, is harmful!”. Interestingly, many patients reported to have had hypoglycemic 
episodes in the previous six months, some of them severe enough to require glucagon injections. 
Although not associated with the psychological dimensions explored in this study, this confirms that 
severe hypoglycemia persists and remains a challenge for patients with type 1 diabetes across their life 
span. Severe DR adds to diabetes in causing discomfort for daily activities. Previous studies exploring 
psychological adjustment in diabetic individuals with visual impairment showed that people with 
diabetes express feelings of uncertainty and vulnerability (30). In our case series, women show a 
perception of worse General Health and pervasive existential distress in their ability to face social 
relationships.  
This study has strengths and limitations. Among the former, a fairly large number of patients examined 
in a multicenter approach, likely to represent most regional situations in Italy. Limitations include the 
cross-sectional approach, which limits the possibility to detect cause-effect relationships. However 
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these results suggest that a wide gap exists between patients’ knowledge and expectations on 
retinopathy on the one side, and health operators’ expertise and assumptions on the other. This is a 
wider problem of organization in the delivery of health care to patients with chronic diseases, which 
poses problems even in the best organized programs to screening for DR (6). Possibly, to bridge this 
gap, patient-centered education and engaging approaches would be much more effective than simple 
information given during consultations (31).  
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Table 1. Socio-Demographic and Clinical data.  
Results are shown relative frequencies (%) for categorical data* and as mean ± SD for continuous variables§  
 
 
°data on Diabetic retinopathy available only for 443 patients 
BCVA: Best Corrected Visual Acuity 
Schooling: Primary and Middle school/ High school/ University degree. 
Occupation:  Housewife and Retired/ Blue-collar worker/ White-collar worker/ Self-Employed/ Others.  
Physical activity: Rarely/ 2/3 time at weeks/ Everyday  
Diabetes visits per year: None / 1 - 2/  3 or more. 















*Gender (men-women) 51.0 – 49.0 48.7 – 51.3 54.8 – 45.2 51.7 – 48.3 47.6 – 52.4 0.785 
§
Age (years) 42.4±12.8 35.1±12.8 44.8±12.3 47.9±9.5 41.6±12.0 <0.001 
§
Duration of diabetes  
(years) 
27.2±13.0 17.4±10.7 30.0±11.0 35.1±10.2 28.8±12.4 <0.001 
BCVA median (IQR) 10 (9;10) 10 (10;10) 10 (9;10) 9 (7;10) 10 (9;10) <0.001 
*Schooling 23.9-49.9-26.2 20.6-45.2-34.2 20.0-53.0-27.0 30.7-50.7-18.7 19.1-61.9-19.0 0.036 
*Living alone (Yes) 52.3 57.9 43.9 51.7 66.7 0.074 
*Occupation 











*Smoking  No/Yes/Former 62.2 - 23.9 - 13.9 64.7 - 28.2 - 7.1 55.6 - 25.2 - 19.1 64.4 - 18.1 - 17.5 57.1 - 33.3 - 9.5 0.017 
*Physical activity 54.9 - 34.8 - 10.3 52.6 - 39.7 - 7.7 55.7 - 31.3 - 13 56 - 34 - 10 71.4 - 19.1 - 9.5 0.406 
*Hypertension 34.5 25.7 35.1 42.0 40.0 0.026 
§
HbA1c (% of total Hb) 7.8±1.3 7.7±1.5 7.8±1.2 7.8±1.1 8.5±2.2 0.0922 
§
HbA1c (mmol/mol) 61.8±14.6 61.0±15.6 61.6±13.2 61.7±12.3 70.2±24.1 0.0836 
*Self-monitoring of blood 
glucose (>4 home tests) 
56.2 61.0 53.0 55.0 47.6 0.488 
Insulin therapy (daily units) 42.3±20.0 38.8±18.0 43.3±18.0 44.6±23.6 42.9±13.7 0.0725 
*Insulin Pump 25.8 33.5 20.5 26.3 15.0 0.066 
*Hypoglicaemia in the last 
six months 
71.2 68.2 67.5 78.2 66.7 0.158 
*Severe hypoglicaemia 
requiring i.m. glucagon 
7.7 7.9 5.3 7.3 23.8 0.035 
*Diabetes visits previous 
year 
5.8 - 37.6 - 56.6 7.1- 36.8 - 56.1 7.0 - 33.0 - 60.0 4.0 - 38.0 - 58.0 4.8 - 57.1 - 38.1 0.419 
*Eye visits previous year 
(>once per year) 
40.0 9.1 39.8 69.8 52.4 <0.001 
*Reason for eye 
consultation 







Table2. The National Eye Institute 25-item Visual Functioning and Locus of Control Questionnaires. Results are shown as mean ± SD and *analysis of 
variance (ANOVA) test.  
 










National Eye Institute 25-item Visual Functioning 
 
General health  57±25.1 54.4±20.6 61.5±25.5 58.3±28.2 NS 
General vision  63.9±19.5 70.3±18.5 64.9±18.6 57.2±17.9 <0.001^^ 
Ocular pain  88.9±13.6 91.7±11.1 90±12.5 85.7±15.1 <0.001^^  
Near vision activities  91.2±15.1 93.2±12.7 94.2±10.2 87.8±18.0 <0.001^^  
Distance vision activities 93.9±11.5 95.1±9.0 95.5±10.0 91.8±13.5 0.008^^  
Visual specific social functioning 98.2±7.8 98.5±6.9 99.2±3.8 97.6±9.0 NS 
Visual specific mental health 86.4±15.6 86.9±14.4 89.2±11.7 84.7±16.5 0.046^ 
Visual specific role difficulties 95.0±13.9 96.4±11.8 96.5±9.4 93.0±17.5 NS 
Visual specific dependency 97.4±10.8 97.8±11.7 98.4±6.9 97.1±10.4 NS 
Driving  92.3±12.9 94.4±9.0 94.1±9.6 89.2±14.9 <0.001^^  
Color vision  98.1±8.1 99.2±4.4 99.6±3.3 95.8±12.4 <0.001^^  
Peripheral vision 93.7±15.7 96.9±10.0 98.0±8.2 87.2±21.8 <0.001^^ 
 
Locus of Control 
 
Internal Control 27.5±5.3 28.4±5.2 27.5±5.0 26.8±5.6 0.038
§
  
Role of Chance 12.4 ±5.2 12.4±5.3 12.7±4.8 12.3±5.4 NS 
Trust in Others 22.8±5.5 22.6±5.2 22.9±6.1 22.9±5.3 NS 
 
° data used for DR sum up to 422, having left out 21 patients with laser treatment and 6 missing 
 
^^significant differences detected between both Severe vs No and Severe vs Mild-Moderate retinopathy group  
^significant differences detected between Severe vs Mild-Moderate retinopathy group 
§













Independent variables – β (CI95%) 
 Diabetic Retinopathy 















Severe Women Years High-univ Yes 
 
Former Yes (%) 
National Eye Institute 25-item Visual Functioning 
 




0.34(0.1;0.6)** -5.1 (-10.9;0.6) -3.3(-9.3;2.7) 
 





-2.3(-6.3;1.7) 0.04(-0.1;0.2) 3.8  (-0.9;8.6) 1.3(-3.6;6.2) 
 
-0.07(-6.0;5.9) -2.1(-6.5;2.3) -1.1(-2.8;0.6) 
Ocular Pain -2.2(-5.8;1.3) 
 
-6.0(-9.7;-2.3)** -1.2(-3.8;1.4) 0.09(-0.03;0.2) 1.9  (-1.1;5.0) 1.6(-1.5;4.7) 
 







-0.8 (-4.0;2.5) 0.3(-3.1;3.7) 
 







0.07(-0.02;0.2) -0.4  (-2.8;2.0) 2.5(0.02;5.0)* 
 







0.05 (-1.3;1.4) 0.6(-0.8;2.0) 
 





-2.1(-6.1;1.9) -2.3(-5.1;0.5) 0.01(-0.1;0.1) -2.7  (-6.0;0.5) 3.2(-0.2;6.5) 
 
-3.8(-8.0;0.3) 0.5(-2.5;3.4) -1.4(-2.5;-0.2)* 
Visual Specific 
Role Difficulties  
0.5(-2.8;3.8) 
 









-0.6(-3.1;2.0) -0.3(-2.1;1.4) 0.03(-0.05;0.1) -1.7 (-3.7;0.4) 1.3(-0.9;3.4) 
 
-1.4(-4.0;1.2) -1.0(-2.8;0.9) -1.5(-2.2;-0.8)*** 
Driving 0.2(-3.4;3.7) 
 
-4.3(-7.9;-0.7)* -3.3(-5.9;-0.8)** -0.04(-0.1;0.1) -1.5 (-4.4;1.5) -0.8(-3.9;2.2) 
 
0.3(-3.4;4.0) -3.4(-6.0;-0.8)* -0.2(-1.4;0.9) 
Color Vision 0.7(-1.4;2.8) 
 
-2.5(-4.6;-0.3)* -0.2(-1.7;1.2) -0.03(-0.1;0.05) -0.8  (-2.6;0.9) -0.6(-2.4;1.2) 
 
-0.7(-2.9;1.5) 1.3(-0.3;2.9) -0.5(-1.1;0.1) 
Peripheral Vision 0.8(-3.2;4.8) 
 
-8.7(-12.9;-4.5)*** -1.5(-4.4;1.4) -0.05(-0.2;0.09) 3.1 (-0.3;6.4) 1.7(-1.8;5.2) 
 
2.3(-2.0;6.7) 0.1(-2.9;3.2) -1.2(-2.4;-0.04)* 
Locus of Control 
 
Internal Control -0.9 (-
2.4;0.6) 
-2.0(-3.6;-0.5)** -1.6(-2.6;-0.5)** 0.02(-0.03;0.07) -1.0(-2.2;0.2) -0.3(-1.6;1.0) 0.1(-1.4;1.7) 0.08(-1.0;1.2) -0.0(-0.4;0.4) 
Role of Chance 0.07 (-
1.4;1.6) 
-0.4(-1.9;1.2) 0.9(-0.1;2.0) -0.0(-0.05;0.05) -1.8(-3.0;-0.5)** 0.6(-0.7;1.8) 0.4(-1.2;2.0) -0.2(-1.3;0.9) 0.5(0.03;0.9)* 
Trust in Others 0.2 (-1.2;1.7) -0.03(-1.6;1.5) -1.3(-2.3;-0.2)* -0.0(-0.06;0.04) -1.4(-2.6;-0.1)* -0.6(-1.9;0.7) -1.3(-2.9;0.3) 1.8(0.7;2.9)** -0.2(-0.7;0.2) 
 
Significance levels are represented as follows: *p<0.05;  **p<0.01; ***p<0.001 
